Hans-Joachim Stemmler
Overview
Explore the profile of Hans-Joachim Stemmler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
819
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kruger S, Angele M, Reu S, Sotlar K, Graser A, Haas M, et al.
Anticancer Drugs
. 2014 Mar;
25(7):854-6.
PMID: 24637577
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare disease. Although most patients eligible for surgery undergo cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy, the role of perioperative systemic chemotherapy...
12.
Horster S, Stemmler H, Strecker N, Brettner F, Hausmann A, Cnossen J, et al.
Crit Care Res Pract
. 2011 Dec;
2012:270631.
PMID: 22191019
USCOM is an ultrasound-based method which has been accepted for noninvasive hemodynamic monitoring in various clinical conditions (USCOM, Ultrasonic cardiac output monitoring). The present study aimed at comparing the accuracy...
13.
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
Modest D, Stintzing S, Laubender R, Neumann J, Jung A, Giessen C, et al.
Anticancer Drugs
. 2011 Jul;
22(9):913-8.
PMID: 21795973
This retrospective study investigated the clinical characteristics of patients with metastatic colorectal cancer (mCRC) depending on the KRAS status, thereby differentiating KRAS exon 2 mutations in codon 12 versus codon...
14.
Geiger S, Cnossen J, Horster S, DiGioia D, Heinemann V, Stemmler H
Anticancer Drugs
. 2011 Jun;
22(9):933-9.
PMID: 21666437
Recent epidemiological studies suggest that chemotherapy for metastatic breast cancer (MBC) has not contributed to a marked improvement in the patient outcome during the last decades. Randomized trials that investigated...
15.
Stemmler H, Harbeck N, Groll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, et al.
Oncology
. 2011 Mar;
79(3-4):204-10.
PMID: 21358208
Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to compare the toxicity and efficacy of...
16.
Stemmler H, Harbeck N, Groll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, et al.
Oncology
. 2011 Mar;
79(3-4):197-203.
PMID: 21358207
Purpose: Previous phase II studies have indicated a greatly reduced hematotoxicity of docetaxel-based regimens administered on weekly schedules. The present trial was initiated to randomly compare the toxicity and efficacy...
17.
Geiger S, Lange V, Suhl P, Heinemann V, Stemmler H
Anticancer Drugs
. 2010 Apr;
21(6):578-90.
PMID: 20375725
Innovative anticancer strategies have contributed to an improved survival of patients suffering from malignancies, and in some cases, have turned cancer into a chronic disease. Therefore, the early and particularly...
18.
Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, et al.
World J Gastroenterol
. 2009 Oct;
15(40):5058-66.
PMID: 19859999
Aim: To investigate the correlation between uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1) gene polymorphisms and irinotecan-associated side effects and parameters of drug efficacy in patients with metastatic colorectal cancer (mCRC)...
19.
Schulz C, Boeck S, Heinemann V, Stemmler H
Anticancer Drugs
. 2009 Sep;
20(10):867-79.
PMID: 19770637
Irinotecan [Camptosar (CPT-11), Pfizer Pharmaceuticals, New York, USA] is one of the most effective chemotherapeutic agents in the treatment of metastatic colorectal cancer. In vivo, the prodrug CPT-11 is biotransformed...
20.
Boeck S, Metzeler K, Hausmann A, Baumann A, Gallmeier E, Parhofer K, et al.
Onkologie
. 2009 Mar;
32(3):125-8.
PMID: 19295253
Background: Cisplatin-based combination chemotherapy is regarded as standard of care for patients with advanced germ cell tumors. In patients with lung metastases and a high tumor load, an association between...